BCL2 and pneumonia: The remaining four patients with migrating pneumonia had received either anti-BCMA agents or venetoclax, a B-cell lymphoma-2 (Bcl-2) inhibitor, all of which have been associated with diminished immune responses to SARS-CoV-2 vaccines [5,6,8], suggesting impaired immune responses to the virus.